Abbott Laboratories leadership

Robert B. Ford has served as Chairman of the Board and Chief Executive Officer of Abbott since December 2021, after serving as President and CEO from 2020 to 2021 and as President and Chief Operating Officer from 2018 to 2020. He previously was Executive Vice President, Medical Devices (2015-2018) and Senior Vice President, Diabetes Care (2014-2015), and has held various leadership roles across Abbott's Diagnostics, Nutrition, and Diabetes Care businesses since joining the company in 1996. He chairs the Board's Executive Committee.

Dr. Ahuja is Dean of the University of Wisconsin School of Medicine and Public Health, Vice Chancellor of Medical Affairs, and Professor in the Department of Surgery since May 2025. She previously chaired the Department of Surgery at Yale School of Medicine (2018-2025) and served as Surgeon-in-Chief for Yale New Haven Health System (2020-2025), and earlier held leadership roles at the Johns Hopkins University School of Medicine. She is an elected member of the National Academy of Medicine and serves on the Board of Directors of the Association of American Medical Colleges. She is an independent director.

Claire Babineaux-Fontenot has been Chief Executive Officer of Feeding America, a U.S. hunger-relief charitable organization, since October 2018, and has announced her retirement after a transition period in 2026. She founded CBF Consulting Group, LLC in 2017 and previously held senior financial roles at Walmart Inc., including Executive Vice President and Global Treasurer (2014-2017) and Senior Vice President and Chief Tax Officer (2007-2014). She serves on the Board of Directors of New York Life Insurance Company and is an independent director, serving on Abbott's Audit and Public Policy Committees.

Dr. Blount has been Chief Executive Officer of Catholic Charities of the Archdiocese of Chicago since 2020 and is the Michael L. Nemmers Professor of Strategy at Northwestern University's J.L. Kellogg Graduate School of Management, where she served as Dean from 2010 to 2018. She previously was Dean of the New York University Undergraduate College and Vice Dean of its Leonard N. Stern School of Business (2004-2010). She served on the Board of Directors of Ulta Beauty, Inc. from 2017 to 2022, and is an independent director on Abbott's Nominations and Governance and Public Policy Committees.

Paola Gonzalez has been Vice President, Global Financial Planning & Analysis of The Clorox Company since June 2023, after serving as Vice President and Treasurer of Clorox (2018-2023) with responsibility for treasury, investor relations, and real estate. She has held various finance leadership roles across Clorox since joining in 1997 and previously worked in finance for American Airlines in Latin America. She is an independent director, serving on Abbott's Audit and Nominations and Governance Committees.

Michelle A. Kumbier is Senior Vice President and President, Turf & Consumer Products of Briggs & Stratton, LLC since March 2022. She previously served as Senior Vice President and Chief Operating Officer of Harley-Davidson Motor Company (2017-2020) and held various other executive roles at Harley-Davidson from 1997 to 2015. She also serves on the boards of Teledyne Technologies Incorporated and Ryerson Holding Corporation, and is an independent director on Abbott's Audit and Compensation Committees.

General Darren W. McDew is a retired four-star general who served 36 years in the U.S. Air Force before retiring in October 2018, including as Commander of U.S. Transportation Command (2015-2018), the single manager for global air, land, and sea transportation for the U.S. Department of Defense. His prior roles included Vice Director for Strategic Plans and Policy for the Joint Chiefs of Staff and Military Aide to the President. He serves on the boards of Parsons Corporation and GE Aerospace, and is an independent director on Abbott's Nominations and Governance and Public Policy Committees.

Nancy McKinstry served as Chief Executive Officer and Chairman of the Executive Board of Wolters Kluwer N.V., a global information, software, and services provider, from September 2003 to February 2026, and was a member of its Executive Board from June 2001. She is a member of the J.P. Morgan International Council and serves on the boards of Accenture plc and Mondelez International, Inc. She is Abbott's Lead Independent Director and chairs the Audit Committee, also serving on the Compensation and Executive Committees.

Michael G. O'Grady is Chairman (since 2019) and Chief Executive Officer (since 2018) of Northern Trust Corporation, a financial services company, where he has also served as President since 2017 and previously as Chief Financial Officer (2011-2014). Before joining Northern Trust he was a Managing Director in the Investment Banking Group of Bank of America Merrill Lynch (2000-2011). He is an independent director on Abbott's Compensation and Nominations and Governance Committees.

Michael F. Roman served as Executive Chairman of the Board of 3M Company from May 2024 to March 2025, and previously as Chairman of the Board, President and Chief Executive Officer of 3M from 2019 to 2024 and CEO from 2018. He also held roles as 3M's Chief Operating Officer and Executive Vice President (2017-2018) and Executive Vice President of its Industrial Business Group (2014-2017). He serves on the board of Waystar Holding Corp. and is an independent director chairing Abbott's Public Policy Committee, also serving on the Compensation and Executive Committees.

Daniel J. Starks served as Executive Chairman of the Board of St. Jude Medical, Inc. from January 2016 until Abbott completed its acquisition of St. Jude Medical in January 2017, and previously as its Chairman, President and Chief Executive Officer from 2004 and as President and Chief Operating Officer from 2001 to 2004. He joined St. Jude Medical in 1996. He is an independent director chairing Abbott's Compensation Committee, and serves on the Public Policy and Executive Committees.

John G. Stratton served as Executive Chairman of Frontier Communications Parent, Inc. from April 2021 to January 2026. He previously held senior roles at Verizon, including Executive Vice President and President of Global Operations (2015-2018), and Chief Operating Officer and Executive Vice President of Verizon Wireless (2010-2012). He was a member of The President's National Security Telecommunications Advisory Committee (2012-2018), serves on the board of General Dynamics Corporation, and is an independent director chairing Abbott's Nominations and Governance Committee while also serving on the Audit and Executive Committees.

Robert J. Alpern, M.D., is an independent director who will continue to serve as a director of Abbott until the 2026 Annual Meeting. The Board determined that he is independent under New York Stock Exchange listing standards.

Philip P. Boudreau is Executive Vice President, Finance and Chief Financial Officer of Abbott and is one of the company's named executive officers for 2025. He was a named executive officer in this finance leadership capacity in prior years reported in the proxy, including 2023 and 2024.

Lisa D. Earnhardt is Executive Vice President and Group President, Medical Devices of Abbott, and is one of the company's named executive officers for 2025. She has been reported as a named executive officer in Abbott's proxy in prior years, including 2023 and 2024.

Daniel G. Salvadori is Executive Vice President and Group President, Established Pharmaceuticals and Nutritional Products of Abbott, and is one of the company's named executive officers for 2025. He has been reported as a named executive officer in Abbott's proxy in multiple prior years, including 2021 through 2024.

Christopher J. Scoggins was appointed Executive Vice President, Diabetes Care of Abbott effective January 1, 2025, and is one of the company's named executive officers for 2025. He previously served as Senior Vice President, Commercial Operations and Marketing, Diabetes Care.

Hubert L. Allen served as Executive Vice President, General Counsel and Secretary of Abbott and is identified in the proxy as a former officer and one of the company's named executive officers for 2025. He was reported as a named executive officer in Abbott's proxy in multiple prior years, including 2021 through 2024.